跳至主要内容
临床试验/NCT06613425
NCT06613425已完成4 期

Combined Platelet Transfusion:A Single-arm, Open, Prospective, Non-inferiority Clinical Trial

The General Hospital of Western Theater Command2 个研究点 分布在 1 个国家目标入组 266 人开始时间: 2024年8月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
266
试验地点
2
主要终点
Efficacy evaluation of combined platelet transfusion

研究概览

简要总结

Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.

详细描述

Combined platelet transfusion is a single-arm, open, prospective, non-inferiority study initiated by researchers. Patients with hematological diseases who were admitted to the research unit and applied for platelet transfusion within two years were included in the study after informed consent. When the subjects applied for platelet transfusion during the study period, ABO homotype platelet transfusion was preferred. When there was no ABO homotype platelet in the inventory, ABO primary and secondary side compatible combined platelet transfusion was given. The study period was 2 years, including 15 months of enrollment, 6 months of treatment, and 3 months of follow-up after the end of the treatment period

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1. Aged 18-65 years;
  • Disease treatment in the research hospital;
  • Applied for platelet transfusion therapy.

排除标准

  • 1. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy;
  • Without platelet transfusion indications;
  • Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion;
  • Gave up platelet transfusion therapy for any reason after enrollment;
  • Transferred or discharged from hospital for any reason before platelet transfusion after enrollment;
  • Did not receive combined platelet transfusion during the 6-month treatment period after enrollment

研究组 & 干预措施

Experimental group

Experimental

Combined platelet

干预措施: Combined platelets (Combination Product)

结局指标

主要结局

Efficacy evaluation of combined platelet transfusion

时间窗: From the start of infusion of combined platelets to 6 months later

The platelet count was measured before blood transfusion and 1 hour and 24 hours after blood transfusion, and the WHO bleeding grade was recorded. The platelet incremental correction index ( CCI ) was calculated at 1 hour and 24 hours after infusion. CCI \> 7.5 at 1 hour, CCI \> 4.5 at 24 hours, or the control or improvement of WHO bleeding symptoms after infusion were effective for infusion. CCI = ( PLT after infusion-PLT before infusion ) × body surface area ( m2 ) × 1000 / total platelet count ( × 1011 ), body surface area = 0.0061 × height ( cm ) + 0.0128 × weight ( Kg ) - 0.1529. PPR ( % ) = ( PLT after infusion-PLT before infusion ) × blood volume ( L ) × 100 % / total platelet count × 2 / 3, blood volume = 0.07 × body weight ( Kg ).

次要结局

  • Interval time, frequency and total amount of platelet transfusion(From the start of infusion of combined platelets to 6 months later)
  • Bleeding adverse events during hospitalization(From the start of infusion of combined platelets to 6 months later)
  • Adverse reactions of blood transfusion(From the start of infusion of combined platelets to 6 months later)
  • Safety evaluation of combined platelet transfusion(From the start of infusion of combined platelets to 6 months later)
  • Platelet antibody screening(From the start of infusion of combined platelets to 6 months later)
  • Adverse events of blood transfusion(From the start of infusion of combined platelets to 6 months later)
  • Waiting time for platelet transfusion(From the start of infusion of combined platelets to 6 months later)

研究者

发起方
The General Hospital of Western Theater Command
申办方类型
Other
责任方
Principal Investigator
主要研究者

zhang li

PHD,Professor

The General Hospital of Western Theater Command

研究点 (2)

Loading locations...

相似试验